Thursday, 5 November 2026European Markets

PETRONOR E&P Stock Is 18% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of PETRONOR E&P (Oslo Børs Benchmark Index_GI: PNOR.OL) rose by a staggering 18.17% in 5 sessions from kr0.68 to kr0.80 at 15:16 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is falling 0.02% to kr1,208.40, after five successive sessions in a row of gains.

PETRONOR E&P's last close was kr0.72, 42.44% under its 52-week high of kr1.25.

About PETRONOR E&P

PetroNor E&P ASA operates as an independent oil and gas exploration and production company in West Africa. It holds exploration and production assets offshore West Africa, primarily the PNGF Sud licenses in Congo Brazzaville, the A4 license in The Gambia, the Sinapa (Block 2) and Esperança (Blocks 4A and 5A) licenses in GuineaBissau, the Rufisque Offshore Profond and Senegal Offshore Sud Profond in Senegal, and OML-113 in Nigeria. The company was founded in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PETRONOR E&P has a trailing twelve months EPS of kr0.02.

PE Ratio

PETRONOR E&P has a trailing twelve months price to earnings ratio of 40. Meaning, the purchaser of the share is investing kr40 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 41.65%.

Volatility

PETRONOR E&P's last week, last month's, and last quarter's current intraday variation average was a positive 3.00%, a negative 0.68%, and a positive 2.11%.

PETRONOR E&P's highest amplitude of average volatility was 3.00% (last week), 2.22% (last month), and 2.11% (last quarter).

More news about PETRONOR E&P (PNOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
PETRONOR E&P Stock Is 18% Up In The Last 5 Sessions | ViaNews EU